Clinical significance of Janus Kinase inhibitor selectivity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.JAMA network open · 2025
   Pooled it
2. The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis.Frontiers in pharmacology · 2022
   Pooled it
3. Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial.Journal of Crohn's & colitis · 2024
   Trial
4. Immunogenetics in psoriasis: towards personalised diagnosis and treatment strategies.Genes and immunity · 2026
   Review
5. Upadacitinib in rheumatoid arthritis: progress and challenges.Frontiers in pharmacology · 2026
   Review
6. SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus.Lupus science & medicine · 2024
   Article
7. Computational insights into rational design and virtual screening of pyrazolopyrimidine derivatives targeting Janus kinase 3 (JAK3).Frontiers in chemistry · 2024
   Article
8. Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis.International journal of molecular sciences · 2023
   Review
9. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.Frontiers in immunology · 2023
   Article
10. JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in anFrontiers in immunology · 2023
    Article
11. Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species.Toxicological sciences : an official journal of the Society of Toxicology · 2022
    Article
12. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.Frontiers in immunology · 2022
    Article
13. Application of Baricitinib in Dermatology.Journal of inflammation research · 2022
    Review
14. Influence of Janus Kinase Inhibitors on the Neuronal Activity as a Proof-of-Concept Model for Itch.Skin pharmacology and physiology · 2022
    Article
15. Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis.Arthritis research & therapy · 2021
    Article
16. Ruxolitinib Alleviates Uveitis Caused byMicroorganisms · 2021
    Article
17. COVID-19: an Immunopathological View.mSphere · 2020
    Review

Corrections and comments

• Erratum for
  Clinical significance of Janus Kinase inhibitor selectivity.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.